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ABSTRACT
The development of oncolytic viruses (OVs) has increased 
significantly in the past 20 years, with many candidates 
entering clinical trials and three of them receiving 
approval for some indications. Recently, OVs have also 
gathered interest as candidates to use in combination with 
immunotherapies for cancer due to their immunogenic 
properties, which include immunogenic cell death and 
the possibility to carry therapeutic transgenes in their 
genomes. OVs transform non- immunogenic ‘cold’ 
tumors into inflamed immunogenic ‘hot’ tumors, where 
immunotherapies show the highest efficacy. However, 
in monotherapy or in combination with immunotherapy, 
OVs face numerous challenges that limit their successful 
application, in particular upon systemic administration, 
such as liver sequestration, neutralizing interactions in 
blood, physical barriers to infection, and fast clearance 
by the immune system. In this regard, the use of 
mesenchymal stem cells (MSCs) as cells carrier for OV 
delivery addresses many of these obstacles acting as virus 
carriers and factories, expressing additional transgenes, 
and modulating the immune system. Here, I review the 
current progress of OVs- loaded MSCs in cancer, focusing 
on their interaction with the immune system, and discuss 
new strategies to improve their therapeutic efficacy.
BACKGROUND
With more than 100 years of history, clinical 
experience using oncolytic viruses (OVs) for 
cancer treatment has alternated periods of 
highs and lows, showing a peak of interest 
during the 1950s and 1960s followed by 
years of abandonment due to poor clinical 
results and severe or even fatal adverse events 
observed after the first clinical trials (1970s 
and 1980s).1 It was not until the advent of 
molecular biology and gene manipulation 
techniques in the late 20th century that 
viruses regained interest as cancer treatments. 
These new techniques allowed scientists not 
only to isolate viruses with a natural selectivity 
for tumor cells, but also to modify existing 
viruses to target and replicate more selectively 
in cancer cells. Furthermore, an increase 
in the knowledge of viral biology allowed 
researchers to substitute viral sequences or 
to incorporate new DNA sequences (trans-
genes) into the viral genome, creating what 
is known as ‘armed’ OVs. These transgenes 
can exert diverse functions such as enhancing 
tumor tropism and penetration, increasing 
viral potency, promoting cell death, and anti- 
angiogenesis, and modulating antitumor 
immunity, among others.2–4
To date, engineered OVs from more than 
10 different viral families have been evaluated 
in phase I–III clinical trials, demonstrating 
favorable safety profiles. However, while local 
OVs administration has shown promising 
results in melanoma patients, systemic OVs 
administration has reported only occasional 
and transient responses.5 The inadequate 
delivery of OVs to the tumor, as a result of 
liver or spleen sequestration, immune system 
recognition and elimination, and poor tumor 
extravasation and spread, has been identified 
as a main factor for insufficient antitumor 
efficacy after systemic OVs administration.3 It 
is, therefore, of clinical relevance to develop 
new strategies to improve OVs bioavailability 
and delivery to tumors, especially for those 
patients where intratumoral injection is not 
feasible or with tumor metastases.
This review will focus on one of these strat-
egies: the use of mesenchymal stem cells 
(MSCs) as cell carriers for OVs and its effect 
on the immune system.
MESENCHYMAL STEM CELLS
As outlined above, OVs face numerous chal-
lenges that hinder their successful systemic 
application. For instance, once adminis-
tered systemically, OVs can be filtered by 
and retained in some tissues, especially the 
liver. The immune system can also recog-
nize these OVs in the bloodstream leading to 
their elimination. Moreover, in order to leave 
the bloodstream and enter the extracellular 
space, OVs have to overcome the abnormal 
tumor vasculature6 and the elevated intersti-
tial fluid pressure.7 Finally, the tumor micro-
environment (TME) bears several barriers 
that limit viral penetration and spreading 
such as an altered tumor extracellular matrix 
(ECM) rich in proteins, hyaluronic acid, 
proteoglycans, and stromal cells.8 Several 
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strategies are being developed in order to overcome these 
barriers (reviewed in9 10). Among them, the use of cell 
carriers for systemic delivery of OVs to the primary tumor 
and metastases represents an attractive system to address 
many of these obstacles. Thus, cell carries could protect 
OVs from complement or neutralizing antibodies, the 
two main viral clearance mechanisms in blood. More-
over, systemic administration of cells loaded with OVs 
could evade the filtering organs, and cross the endothe-
lial barrier thanks to their capability to traffic towards 
different tissues and organs following chemokine gradi-
ents or using cell surface adhesion proteins. Finally, some 
types of cells have gained interest due to their ability to 
specifically migrate toward tumors such as immune cells 
(T cells and macrophages), progenitor cells, cancer cells, 
and more recently neural stem cells and MSCs.11 12 From 
the plethora of cells used as cell carriers, MSCs are of 
particular interest because of their inherent properties, 
which will be discussed in the next section.
MSCs: origin and properties
In the 1970s, a novel subset of non- hematopoietic stem 
cells with a multilineage potential was described in the 
marrow stroma by Friedenstein and co- workers.13 They 
reported an adherent fibroblast- like cell with the ability 
to generate colonies in vitro (figure 1). These cells, 
defined as colony- forming unit fibroblasts, demonstrated 
later the ability to differentiate both in vitro and in vivo 
into a variety of cell types of mesenchymal origin such as 
adipocytes, chondrocytes, osteocytes, and tenocytes, and 
into other cell types such as cardiomyocytes, myocytes, 
astrocytes, and neurons, among others.14 It was at the 
end of the 1980s when further studies led to characterize 
the heterogeneity of the marrow stromal cell pool and to 
identify a stem cell population with a mesodermal germ 
layer origin that contributed to the formation of connec-
tive tissue, skeletal muscle cells, and vascular system. 
These cells are known as marrow stroma stem cells or 
bone marrow- derived MSCs (BM- MSCs).15 16 Of special 
interest were the experiments performed by several 
groups showing that BM- MSCs had unique immunomod-
ulatory properties in an allogeneic transplant.17
During the following decades, and thanks to their 
adherence properties and to new MSCs isolation proce-
dures, an increasing number of human MSCs were iden-
tified from diverse organs and tissues such as adipose 
tissue, muscle, liver, periosteum, dental pulp, perichon-
drium, menstrual blood, etc.18 MSCs were also described 
in fetal fluids and tissues, including amniotic fluid, cord 
blood, placenta, bone marrow, blood, liver, and lung.19 20 
Interestingly, although both fetal and adult MSCs share 
Figure 1 Mesenchymal stem cells (MSCs): origin, stem cell potential, and immunomodulatory properties. (A) MSCs can 
be easily isolated from diverse adult and fetal tissues, thanks to their adherence ability. Once isolated, and according to the 
International Society for Cellular Therapy guideline, MSCs are phenotypically characterized as CD90+, CD105+, CD73+, CD45−, 
CD19−, CD14−, c- kit−, CD11b−, CD79α−, CD34−, and HLA- DR−. (B) MSCs are described as multipotent stem cells with the 
potential for self- renew and to differentiate into several cell types. (C) The lack of HLA- II and costimulatory molecules (CD40, 
CD80, and CD86) confers immune evasive properties to MSCs. Moreover, through the secretion of cytokines, chemokines, and 
growth factors, the production of extracellular vesicles, exosomes, and microRNAs, and the expression of cell surface proteins, 
MSCs exert immunomodulatory functions interfering with different pathways of the immune response. (D) In response to 
inflammatory signals expressed and secreted by tumor cells, MSCs have the potential to migrate to and to propagate within the 
tumor mass. DC, dendritic cell; HLA- DR, human leukocyte antigen- DR; NK: natural killer; Treg, regulatory T cells.
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immunological attributes,21 those from fetal origin are 
present in higher amounts and have shorter cell doubling 
time and higher proliferative capacity than those from 
adult tissues.22
To date, there are no unique markers to unequivocally 
identify MSCs and the presence or the absence of a set 
of non- specific markers are required to phenotypically 
characterize them. This challenging phenotypic marker 
landscape has prevented the proper identification of 
MSCs isolated from different laboratories.23 In 2006, 
the International Society for Cellular Therapy defined 
MSCs as self- renewing multipotent fibroblast- like cells 
with plastic adherent capacity, capable to differentiate, at 
least, into adipocytes, osteocytes, and chondrocytes, posi-
tive for expression of CD90, CD105, and CD73, and nega-
tive for CD45, CD19, CD14, c- kit, CD11b, CD79α, CD34 
(except adipose tissue- derived MSCs that express CD34 
in short- term cultures), and human leukocyte antigen- DR 
(HLA- DR).24
MSCs present unique immunological and immunomod-
ulatory functions. Thus, MSCs are considered to have low 
immunogenicity owing to the lack of expression of HLA 
class II, CD40, CD80, and CD86 co- stimulatory mole-
cules, and low levels of expression of HLA class I on their 
surface.25 Although it has been widely considered that 
this immunological privileged phenotype allows MSCs to 
evade immune system recognition, recent reports have 
shown that MSCs can elicit both humoral and cellular 
immune responses, thus suggesting an immune evasive 
rather than an immune privileged immunophenotype.26
MSCs also exert immunomodulatory functions over 
almost all immune cells through cell- to- cell contact and 
by secreting a wide variety of cytokines, chemokines, and 
growth factors. Thus, MSCs have been described to regu-
late the activity of naïve, memory, and effector T cells, B 
cells, regulatory T cells (Tregs), natural killer cells (NKs), 
dendritic cells, monocytes/macrophages, and neutro-
phils.27 28
Finally, and of special interest for systemic cancer 
treatment, MSCs are known to migrate to sites of injury 
and inflammation, which are two traits of the TME.29 
MSCs respond to inflammation mediators that are 
highly expressed in the tumor such as growth factors 
(vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), granulocyte–macrophage colony- 
stimulating factor, hematopoietic growth factor, hepato-
cyte growth factor (HGF), epidermal growth factor 
(EGF), transforming growth factor beta-1 (TGF-β1), 
granulocyte colony- stimulating factor or stromal- derived 
growth factor-1α), chemokines (CCL2, CCL3, and CXCL-
12), cytokines (interleukin 6 (IL-6) and IL-8), integrins 
(vascular cell adhesion molecule 1 (VCAM-1) and intracel-
lular adhesion molecule-1 (ICAM-1)), and selectins (P- se-
lectin and E- selectin).30 In response to these local tumor 
inflammatory mediators, MSCs initiate a rolling process 
similar to that described for leukocytes in response also 
to inflammation, whereby MSCs adhere to the vascular 
epithelium and begin transmigration into the tumor.31 
Evidence of MSCs tumor migration has been reported 
for several cancer types, pointing out their potential as 
delivery vectors for antitumor therapies.32
Their easy isolation and expansion, in addition to their 
immune evading properties and their ability to migrate 
to the tumor, make MSCs particularly appealing as cell 
carriers for OVs.
MSCs and cancer
The effect of MSCs on tumor progression has been a 
controversial field for the last decades, with several studies 
suggesting a role of MSCs in promoting tumor growth 
and metastasis, while others support their antitumor 
potential.33 In recent years, the pro- tumorigenic theory 
has gained force based on studies that demonstrate the 
effect of MSCs in the TME and its regulation in tumor 
immunosurveillance.
Modulation of the TME by MSCs
To better understand the effect of MSCs on the TME, it is 
important to note that tumors have long been considered 
as a wound process that fails to resolve.34 35 Thus, it has 
been described how wound healing and tumor progres-
sion share common traits like inflammation, tissue prolif-
eration and remodeling, ECM remodeling, immune cell 
mobilization and activation, and neovascularization. 
However, while this is a well- defined process for wound 
healing, in cancer this process is not properly completed 
and becomes an unresolved situation.
MSCs contribution to tumor inflammation, tissue 
proliferation and remodeling steps have been extensively 
reviewed by Li et al,36 who highlight the key role of tumor- 
associated MSCs (TA- MSCs) at the first stages of cancer 
development. TA- MSCs in the tumor inflammatory 
microenvironment secrete cytokines and chemokines 
such as IL-6, HGF, CCL-2, CXCL1/2, HGF, or CXCL3, 
that promote infiltration of myeloid- derived suppressor 
cells (MDSCs) and monocytes, and differentiation of 
the latter to M2 macrophages. Additionally, TA- MSCs 
participate in recruiting new MSCs to tumors where they 
support tumor proliferation through their transdifferen-
tiation into tumor cancer- associated fibroblasts, which in 
turn provide survival and proliferative signals to cancer 
stem cells by secreting growth factors and cytokines such 
as HGF, TGF-β, FGF, IL-6, IL-8, CXCL1/7, and bone 
morphogenetic protein. TA- MSCs and recruited MSCs 
also secrete VEGF and platelet- derived growth factor, 
which support the neovascularization of the growing 
tumor. In the last step of tumor progression, the remod-
eling step, MSCs role is contradictory. On one hand, 
TA- MSCs release exosomes containing microRNAs, which 
reduce the tumor growth rate by promoting a dormancy 
phenotype in tumor cells, and also inhibit angiogenesis. 
These antitumoral functions are considered a reminis-
cence of their anti- inflammatory cellular program. On the 
other hand, TA- MSCs secrete chemokines (CCL-2, CCL-5, 
CCL9, and CXCL10) and cytokines (IL-8, IL-1β, tumor 
necrosis factor- alpha (TNFα), and TNFβ) that stimulate 
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the epithelial–mesenchymal transition, increasing tumor 
cell invasion and metastasis.
Regulation of tumor surveillance by MSCs
Cytokines and exosomes secreted by TA- MSCs, as a 
result of their crosstalk with tumor cells, modulate the 
tumor surveillance acting on different players of the 
innate and the adaptive immune system.37 Regarding 
the innate immune system, TA- MSCs stimulate recruit-
ment and differentiation of immunosuppressive macro-
phages M2, via secretion of prostaglandin E2 (PGE2) 
and exosomes,38 39 and of MDSCs, through the secre-
tion of HGF and CXCL3.40 Moreover, IL-6, PGE2, and 
microRNAs secreted by MSCs also prevent differentiation 
of monocytes to dendritic cells (DCs), and maturation 
of immature into mature DCs.41 TGF-β, IL-6, PGE2, and 
microRNAs secreted by TA- MSCs are responsible for the 
impaired function of NK cells, in some cases downreg-
ulating the expression of activating NK cell receptors: 
NKp44, NKp30, NKG2D, DNAX accessory molecule-1 
(DNAM- I), and NKG2A.42 43 Finally, MSCs exert a potent 
γδ-T cell immunosuppression through cyclooxygenase-2 
(COX2)- dependent production of PGE2.44
MSCs also immunosuppress the adaptive immunity 
in the tumor. MSCs can inhibit naïve and memory T 
cell responses by upregulating lymphocyte function- 
associated 3, ICAM-1, and VCAM-1.45 46 Additionally, 
TA- MSCs impair correct effector lymphocyte activation by 
secreting inhibiting factors such as TGF-β, PGE2, IL-10, 
indoleamine 2,3- dioxygenase and nitric oxide.45 Further-
more, TA- MSCs exert a potent TME immunosuppressive 
effect by increasing the amount of Tregs in the tumor.47
Altogether, these MSC functions in the TME support 
the role of MSCs in tumor progression and spread. There-
fore, it is necessary to carefully modify MSCs prior to their 
application as antitumor therapies, by knocking down 
some of these pro- tumoral properties, inserting suicide 
gene as ‘safety switch’, or combining with OVs that eventu-
ally eliminate infected MSC during the treatment. In line 
with this, modified MSCs have been evaluated in several 
animal models,30 and their safety and efficacy have been 
reported in early clinical trials for cancer treatment.48 
No malignant or pro- tumoral effects have been reported 
from any of these studies, indicating that modified MSCs 
lack the tumor- promoting properties described above.
APPLICATION OF MSCS AS CELL CARRIER FOR SYSTEMIC 
DELIVERY OF OVS
To serve as efficient cell carriers for OVs delivery to 
tumors on systemic administration, MSCs should fulfill 
the following requirements: (1) efficient infectivity, (2) 
allow OV replication and production, (3) modulate the 
immune response against the virus, and (4) promote an 
antitumor immune response (figure 2).
Although multiple types of viruses can be combined 
with MSCs, there are different factors that should be 
considered to maximize the benefit of the combination. 
Thus, viral genome type is an important consideration 
since RNA viruses replicate faster than DNA viruses, 
allowing less time for MSCs to reach the tumor. Choosing 
OVs capable of infecting and replicating properly in 
MSCs is needed in order to ensure an optimal tumor viral 
delivery. Delivery via MSCs is specifically suitable for those 
viruses lacking tumor tropism, since they could benefit 
from MSCs tumor homing properties, not only in terms 
of tumor delivery but also to avoid normal organ infec-
tion. Finally, the use of MSCs as cell vehicles represents 
a particular advantage for viruses commonly infecting 
humans where pre- immunity in the population is broadly 
present, such as measles virus (MV) or adenovirus (Ad).
Several preclinical studies have evaluated the combina-
tion of human MSCs and OVs in the setting of systemic 
administration (online supplemental table 1).
Myxoma virus (MYXV)
MYXV expressing green fluorescent protein (GFP) as 
reporter gene has been combined with human adipose- 
derived MSCs (ASCs) to treat malignant brain tumor in 
mice.49 This study demonstrated not only the capability 
of ASCs to generate new viral particles, but also the 
tumor- homing properties of infected cells on intracra-
nial administration. As a result, a significant increase in 
survival was observed in mice treated with the OV- loaded 
MSCs in comparison with mice treated with MSCs alone.
BM- MSCs have also shown to be permissive to MYXV 
replication.49 Moreover, using an IL-15- armed MYXV to 
infect BM- MSCs, the authors demonstrated a superior 
Figure 2 To be considered as efficient cell carriers for OVs, 
MSCs have to be permissive to infection and replication of 
the OV of choice. Moreover, on systemic administration, 
MSCs must protect the OV from immune system recognition 
in order to have successful tumor delivery. Once in the tumor, 
MSCs should spread to favor a homogeneous production of 
new viral particles within the tumor mass. Finally, a desirable 
property for ideal OV cell carriers is the capacity to stimulate 
or promote tumor immune system recognition and eventually 
antitumor immune response. DC, dendritic cell; MSCs, 
mesenchymal stem cells; NK, natural killer; OV, oncolytic 
virus.
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antitumor efficacy in an immune competent pulmonary 
melanoma model after intravenous treatment, compared 
with MYXV monotherapy. An elevated percentage of 
circulating NK cells was observed only in those animals 
treated with the virus without cell carriers, indicating that 
MSCs potentially prevented recognition of the virus by the 
immune system. Finally, an increase of pro- inflammatory 
cytokines (interferon (IFN)-γ and TNFα), programmed 
cell death protein 1 (PD-1)/programmed death- ligand 1 
(PD- L1), and effector T cells infiltration was documented 
only in tumors from animals treated with MYXV- IL-15- 
loaded MSCs, indicating a possible antitumor immune 
response as a consequence of the therapy.
Herpes simplex virus (HSV)
Two different studies have demonstrated the antitumor 
potential of the combination of HSV and MSCs. Leoni 
and co- workers infected fetal membrane- derived MSCs 
(FM- MSCs) with an HSV encoding for a single- chain anti-
body targeting human epidermal growth factor receptor 
2 (HER-2) (R- LM249).50 FM- MSCs viral infection, viral 
progeny production, and tumor viral delivery were demon-
strated. The antitumor efficacy on intravenous adminis-
tration was evaluated in two different mice models. In a 
lung metastases model (using the HER-2 positive SK- OV-3 
cell line), R- LM249- infected MSCs significantly inhibited 
the appearance of metastasis, unlike uninfected MSCs. 
Similar results were observed in a model of brain metas-
tasis (HER2+ MDA- MB-453 EGFP cell line), in which 
R- LM249- infected FM- MSCs prevented the development 
of brain metastases. In a second study, Du et al reported 
MSC- mediated delivery of oncolytic- HSV to brain metas-
tases in a murine model of melanoma after a intracarotid 
single administration.51 This tumor delivery resulted in 
a significant remission of metastatic tumors and mice 
survival in comparison to MSCs- treated alone.
Measles virus (MV)
MSCs from diverse origins have been combined with MV 
for cancer treatment. Two groups have evaluated intra-
venous single administration of MV- loaded BM- MSCs in 
hepatocellular carcinoma and lymphoblastic leukemia 
mouse models.52 53 Both studies reported BM- MSCs 
permissiveness for virus replication and, most importantly, 
virus delivery to tumors and higher therapeutic efficacy 
than cell- free MV in the presence of pre- existing neutral-
izing anti- MV antibodies. MSCs from adipose tissue have 
also been combined with MV. Mader et al tested MV- in-
fected ASCs antitumor potential in a xenograft murine 
model of ovarian cancer after a single intraperitoneal 
administration.54 In line with the studies described above, 
the use of ASCs as cell carriers not only enhanced the 
therapeutic potential in comparison with virus alone 
treatment, but also the capacity to protect the virus from 
pre- existing antiviral immunity. In a follow- up study, the 
same authors pointed out the feasibility of using patient- 
derived MSC as carriers for MV.55
Importantly, these three studies show for the first time 
the advantage of using MSCs as cell carriers when viral 
pre- immunity exists.
Adenovirus (Ad)
Oncolytic Ads (OAds) have been the most frequently 
used viruses in combination with MSCs for cancer treat-
ment. Pioneer studies in 2007 compared Ad infectivity 
and viral production in MSCs using chimeric or modified 
adenoviral fibers.56 57 These studies also highlighted the 
capacity of OAd- loaded MSCs to reach the tumor after 
single intravenous administration, and to reduce tumor 
growth in lung and breast tumor murine models.
The group of Frederick Lang evaluated the combi-
nation of BM- MSCs with the OAd delta-24/RGD. In a 
first work using two different glioma xenograft murine 
models (U87 and U215- V121), the authors detected brain 
tumor tropism and antitumor activity of infected MSCs 
after single intracarotid administration.58 A second study 
demonstrated a main role of TGF-β secreted by glioma 
stem cells in the BM- MSCs glioma tropism.59
Bolontrade et al described a subpopulation of 
BM- MSCs, overexpressing integrins α2, α3, and α5, with 
and enhanced tumor migration capacity.60 Loading these 
cells with an OAd led to a significant therapeutic efficacy 
compared with unloaded MSCs and virus as monothera-
pies in a melanoma xenograft model after a single retro 
orbital administration.
Hypoxic conditions have been also reported to favor 
MSCs tumor- homing properties by inducing the upreg-
ulation of CXCR4 and CXCR1 receptors.61 However, the 
combination of an E1B- 55KD- deleted OAd with BM- MSCs 
cultured under hypoxic conditions did not control tumor 
growth after a single intraperitoneal administration in 
a xenograft model of colon cancer. Authors attributed 
the low potency of the virus as a possible explanation for 
this low efficacy, although no control group with virus 
as monotherapy was included in the study. The combi-
nation with a more potent OAd would have been desir-
able to demonstrate the benefit of culturing BM- MSCs in 
hypoxia for this type of cancer therapy.
Hepatocellular carcinoma murine models have been 
used to evaluate the efficacy of umbilical cord- derived 
MSCs (HU- MSCs) and BM- MSCs loaded with different 
OAds. Combining an OAd expressing IL-24 with HU- MSCs 
engineered to express the E1A adenoviral protein, Li 
and colleagues reported successful virus replication and 
virus production, and efficient migration of virus- loaded 
HU- MSCs to tumors after a single intravenous administra-
tion.62 Furthermore, addition of a low- dose 5- fluorouracil 
to the OAdv- infected HU- MSCs combination resulted in 
effective tumor growth inhibition. HU- MSCs were also 
combined with an OAd expressing a microRNA-122 target 
sequence to avoid virus replication in normal liver cells.63 
Significant antitumor efficacy was reported after two 
intravenous administrations using orthotopic and subcu-
taneous hepatocarcinoma tumor models, although direct 
comparison with virus alone was not performed. Finally, 
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BM- MSCs as cell carriers for an OAd encoding a WNT- 
inhibiting (WNTi) decoy receptor have been tested in an 
orthotopic hepatocellular carcinoma. After optimizing 
the OAd dose for loading into BM- MSCS, two intravenous 
administrations of OAd- WNTi- loaded BM- MSC showed 
remarkable therapeutic efficacy in vivo64 . Interestingly, 
direct comparison with OAd- WNTi without cell carriers 
showed 8.1- fold greater therapeutic efficacy for cell- 
protected viruses compared with the ‘naked’ virus group. 
Moreover, MSCs efficiently extended OAd blood circu-
lation time while preventing hepatic damage in compar-
ison with direct virus administration. In a follow- up study, 
the same group used a dynamic in silico TME model 
interaction network and a predictive mathematical model 
to identify two parameters to improve the outcome: the 
multiplicity of infection used to infect MSCs and the 
number of OAd- MSCs administered.65
Ad/RLX, an OAd coding for relaxin, a peptide 
hormone with ECM collagen degradation properties, has 
been combined with BM- MSCs for preclinical pancreatic 
cancer treatment.66 Nude mice carrying AsPC-1 pancre-
atic xenograft tumors received three intravenously admin-
istration of naked Ad/RLX, Ad/RLX- loaded BM- MSCs 
or BM- MSCs infected with Ad/RLX previously treated 
with poly(ethyleneimine)- conjugated poly(CBA- DAH) 
(PCDP), a cationic polymer that increases MSCs viral 
infectivity. Significant antitumor efficacy was observed 
only for the last group, probably due to the higher MSCs 
infectivity and viral production of PCDP- treated Ad/RLX.
Using xenograft chick embryo model of pancreatic 
cancer, Kaczorowski et al showed the capacity of OAd- 
infected BM- MSCs to invade tumor spheroids gener-
ating new viral particles in the tumor.67 Moreover, using 
a chimeric OAd (fiber 5/3) expressing TNF- related 
apoptosis- inducing ligand as load for BM- MSCs, increased 
tumor reduction was determined compared with the virus 
monotherapy.
MSCs isolated from menstrual blood (MenSCs) have 
been also used as cell carriers for OAd. Guo et al used 
MenSCs for tumor delivery of a chimeric OAd in murine 
models of colorectal cancer.68 After intravenous or intra-
peritoneal administration, correct MSCs tumor migration 
was determined. Moreover, two intravenous administra-
tions of Ad5/F11- infected MenSCs resulted in significant 
antitumor efficacy although viral treatment alone was not 
included in the study as a control.
ICOVIR15, an E1a/delta24- modified promoter and 
RGD fiber OAd, has been used in combination with 
MSCs for cancer treatment. The group of M Brenner 
used BM- MSCs infected with an ICOVIR15 engi-
neered to express an inducible Caspase 9 suicide gene 
(ICOVIR15- Ad.iC91) for preclinical lung cancer treat-
ment.69 After one single intravenous administration, 
MSCs could be detected in tumor tissues and higher 
tumor control was observed in animals treated with 
ICOVIR15- Ad.iC9- MSCs.
We have focused on using MenSCs as an alterna-
tive ICOVIR15 cell carrier. In a first study, viral capsid 
modifications were compared to select the most efficient 
in terms of MSCs infection and viral progeny produc-
tion.70 Using a lung xenograft murine model, tumor 
homing potential of uninfected and infected MenSCs 
was demonstrated after intraperitoneal administration. 
A subsequent study reported the benefit of using allo-
geneic instead of autologous MenSCs, as a consequence 
of the higher pro- inflammatory environment generated 
when OAd- loaded MenSCs interacted with allogeneic 
peripheral blood mononuclear cells (PBMCs).71 Acti-
vation of both T cells and NK cells was associated with 
this pro- inflammatory MSCs phenotype indicating the 
potential capability of Ad- infected MSCs to favor tumor 
immune recognition. The therapeutic potential of OAd- 
MenSCs was demonstrated in tumor- bearing NSG mice 
who received intravenous injections of allogeneic human 
PBMCs. Monocytes and NK cells contributed to effi-
cacy. Finally, the therapeutic potential of OAd- MenSCs 
has been further improved by loading MenSCs with an 
ICOVIR15 oncolytic vector engineered to express an EGF 
receptor- targeting bispecific T cell engager (cBiTE). Anti-
tumor efficacy of ICOVIR15- cBiTE MenSCs was superior 
to both monotherapy controls. Altogether, these results 
suggest that to improve viral- loaded MSCs therapy OAd 
should be optimized.72
Finally, two different groups have demonstrated the 
preclinical benefit of using OAd- loaded MSCs to treat 
brain tumors after local or intratumoral administration. 
Sonabend and co- workers reported that injecting OAd- 
MSCs 5 mm away from brain lesions, promote cell migra-
tion to the tumor which results in local virus production. 
No efficacy experiment was performed in this study. More 
recently, Martinez- Quintanilla et al employed ICOVIR17, 
an ICOVIR15 modified to encode for soluble hyaluro-
nidase PH20 that mediates ECM hyaluronic acid degra-
dation, in combination with ASCs to treat glioblastoma 
(GBM) intratumorally.73 A significant antitumor efficacy 
was observed in mice bearing intracranial U87 tumors or 
patient- derived GBM xenografts.
In summary, MSCs from diverse origins have demon-
strated potential as cell carriers for RNA or DNA OVs with 
different degrees of lytic properties (ie, low or high),74 
highlighting the versatility of these cells to combine with 
OVs.
CLINICAL EXPERIENCE USING MSCS AS CELL CARRIER FOR 
OVS
According to the  clinicaltrials. org database, there are six 
registered clinical trials (completed or recruiting) eval-
uating the safety and therapeutic efficacy of OVs using 
MSCs as cell carriers for cancer treatment (online supple-
mental table 2).
BM- MSCs carrying ICOVIR-5, an OAd,75 have been eval-
uated in four cancer clinical trials. The first trial assessed 
the use of CELYVIR (X- ray irradiated ICOVIR-5- loaded 
autologous BM- MSCs) to treat pediatric refractory neuro-
blastoma. Clinical results from the first four patients 
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treated (refractory stage IV neuroblastoma, pre- treated 
with at least two front- line multichemotherapy before 
CELYVIR) revealed the absence of toxicity or disease 
progression related to the infusion of CELYVIR.76 The 
first enrolled patient experienced a partial remission after 
the third CELYVIR infusion which turned into a complete 
response after standard consolidation with high- dose 
chemotherapy, highlighting the therapeutic potential of 
the therapy. An immune response secondary to the inflam-
matory oncolysis produced by ICOVIR-5 was suggested as 
a major therapeutic mechanism. Clinical outcome from 
additional 12 patients treated with CELYVIR showed 
eight progressive diseases (PDs), one stable disease (SD), 
three partial responses (PR), and one complete response 
(CR).77 Secondary peaks of viral replication were detected 
in 7 out of 12 patients 7 days after CELYVIR infusions, 
without differences between responder (SD+PR+CR) and 
non- responder (PD). Biomarker analysis revealed sugges-
tive factors associated to response, including MSCs high 
expression levels of two chemokine receptors (CCR1 and 
CXCR1, both directly involved in MSCs tumor homing 
ability), higher number of circulating T cells at baseline, 
and a less pro- inflammatory MSC profile after adenoviral 
infection. It is important to note that no correlative anal-
ysis and clinical outcome were performed due to small 
patient population.
A second completed study using CELYVIR for systemic 
treatment of adult and pediatric advance solid tumors 
has been reported (NCT01844661).78 Nine pediatric and 
seven adult patients completed the therapy (CELYVIR 
once weekly for six cycles). No grade 2–5 toxicities related 
to CELYVIR were reported confirming the treatment 
safety. Second wave of Ad replication was detected in seven 
out of nine pediatric patients but not in adult patients. 
Regarding antitumor efficacy, two pediatric patients 
(neuroblastoma) and one adult patient (anaplastic astro-
cytoma) showed stabilization of the disease. Because of 
the small sample and limited clinical outcome, no conclu-
sion could be drawn from this trial, and a phase II trial has 
been proposed to further evaluate the therapy benefit.
Although the presence of infected BM- MSCs in the 
tumor has not been measured in these complete trials, 
the clinical outcome does not seem to be directly related 
with the CELYVIR doses received. Assuming a dose- 
dependent homing of MSC to tumors, this lack of dose- 
dependent clinical response points to other factors rather 
than the amount of modified MSCs in the tumor that 
could contribute to the efficacy.
Two additional trials using ICOVIR5 are ongoing, in 
which allogeneic, instead of autologous, BM- MSCs are 
used as carriers (defined as aloCELYVIR). In the first one, 
aloCELYVIR is combined with chemotherapy and radio-
therapy for the treatment of children and adolescents 
with relapsed or refractory extracranial solid tumors 
(EudraCT number: 2019-001154-26). In the second one, 
aloCELYVIR is used to treat patients with metastatic uveal 
melanoma (EudraCT number: 2020-005207-39). No 
results have been reported thus far.
Combination of allogeneic BM- MSCs and the OAd 
DNX-2401 (a delta24- RGD Ad) is being evaluated in 
patients with recurrent GBM, gliosarcoma, or wild- type 
IDH-1 anaplastic astrocytoma in a phase I clinical trial 
(NCT03896568). No results have been disclosed yet.
Finally, phase I/II clinical trial is ongoing evaluating the 
use of ASCs as cell carriers for MV- NIS, an MV encoding 
thyroidal sodium iodide symporter (NCT02068794). The 
primary objectives of this trial are to determine the maxi-
mally tolerated dose of ASC- loaded MV- NIS intraperito-
neally administered (phase I), and to assess the 4- month 
progression free survival of ovarian cancer patients 
treated with this therapy in a phase II expansion cohort. 
Interestingly, one of the tertiary objectives of the trial is to 
assess biodistribution of virally infected cells using single- 
photon emission CT/CT imaging, which could show for 
the first time the MSCs tumor tropism in patients, vali-
dating the use of radionuclide reporter genes to track 
OV- loaded MSCs kinetics in clinical trials. The interim 
analysis for this study is expected in early 2021.
CONCLUSIONS AND FUTURE DIRECTIONS
Although the number of preclinical studies evaluating 
the use of MSCs as cell carriers for OVs is limited, this 
strategy has demonstrated superior to direct OV adminis-
tration in those studies where both therapies were directly 
compared. Additionally, data from clinical studies using 
OV- loaded MSCs have shown systemic protection of the 
virus from neutralizing immune responses and clinical 
benefit, including a complete response. Of note, this clin-
ical efficacy has been obtained using ‘non- armed’ OVs 
designed more than a decade ago. Therefore, a logical 
next step aiming at improving clinical outcome should 
focus on combining MSCs with more potent OVs. The 
number of armed and genetically modified OVs under 
clinical investigation to date is extensive,3 which opens a 
wide variety of opportunities for combinations with MSCs.
It is also possible to improve the clinical outcome by 
optimizing the MSCs. Although bone marrow represents 
the main and most frequent source for MSCs isolation 
and amplification, new sources are emerging as excellent 
candidates for MSC isolation because are less invasive or 
render MSCs with higher amplification potential, such as 
adipose tissue and menstrual blood. MSCs subpopulations 
enriched in integrins60 or growing MSCs under hypoxic 
conditions61 could be considered excellent approaches to 
enhance MSCs tumor tropism. In this scenario, it is even 
more interesting to have an abundant source for MSCs 
that can be enriched in the subpopulation of interest, such 
as menstrual blood with millions of potential monthly 
donors. Infectivity and viral production could be also opti-
mized using polymers or different viral capsids.66 70 Finally, 
the protumoral phenotype of MSCs could be converted to 
an antitumoral one under certain conditions according 
to the new paradigm for MSCs described in 2010 by the 
group of Betancourt.79 80 This group described how using 
diverse Toll- like receptor (TLR) agonists, MSCs could be 
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polarized into a pro- inflammatory MSC1 or an immu-
nosuppressive MSC2 phenotype, with MSC1 showing 
antitumor potential, whereas MSC2 promoting tumor 
growth and metastasis.81 This theory was demonstrated 
for TLR4- primed MSCs (polarized toward a MSC1- tumor 
growth inhibition phenotype) and TLR3- primed MSCs 
(polarized toward a MSC2 immunosuppressive pheno-
type).82 Recently, we also showed how infection by an 
OAds induces TLR9 overexpression and activation of the 
NF-κB pathway in menstrual blood- derived MSCs leading 
to a specific cytokine secretion profile and T cells and 
NK cells activation.71 Therefore, blocking or activating 
specific MSCs TLRs might be an effective strategy to add 
MSCs immune- stimulatory properties to OV oncolysis in 
order to enhance the therapy antitumor potential.
In conclusion, although results from ongoing clinical 
trials will better define the clinical potential of MSCs 
as cell carriers of OVs, new efforts should be made in 
order to translate recent viral and cellular preclinical 
improvements to the clinic, either in monotherapy or in 
combination with radiotherapy, chemotherapy or even 
immunotherapies.
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